Navigation Links
Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
Date:10/18/2010

DURHAM, N.C., Oct. 18 /PRNewswire/ -- Argos Therapeutics today announced that Jeff Abbey, the company's president and chief executive officer, will present an overview of its Arcelis™ dendritic cell-based immunotherapy at 3:30 p.m. EDT on Oct. 21 at the inaugural Cancer Immunotherapy Conference in New York.

In addition, Charles Nicolette, Ph.D., the company's chief scientific officer and vice president of research and development, will participate in a panel discussion titled "Autologous versus allogeneic immunotherapy" at 2:45 p.m. EDT that day. The conference will take place at the New York Academy of Medicine. A live Webcast of the conference can be accessed by visiting www.mdbpartners.com/vaccine.

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com Contacts:David Schull or Andreas MarathovouniotisRusso Partners LLC(212) 845-4271 or (212) 845-4235david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.comJeff AbbeyArgos Therapeutics(919) 287-6308jabbey@argostherapeutics.com
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
2. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
3. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
4. Prime Therapeutics Announces URAC Accreditation
5. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
6. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
7. Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
8. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
9. Prime Therapeutics Hires Peter Wickersham, Senior Vice President Cost of Care
10. Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill
11. Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  The U.S. Food and Drug Administration today ... of adults and pediatric patients 12 years and older ... have not received prior chemotherapy. This is the first ... of skin cancer. "While skin cancer is ... rare form called Merkel cell cancer have not had ...
(Date:3/23/2017)... , March 23, 2017   BioSpace , ... resource, has partnered with Indiana Biosciences Research Institute ... organizations and educational institutions to bring the state,s ... first-ever BioIndiana Hotbed map, an artistic representation of the ... was presented to Vice President Mike Pence , ...
(Date:3/23/2017)... Texas , March 23, 2017  Digital ... www.digitalpharmacist.com ), a rapidly growing digital health ... a mobile app that allows patients to manage ... multi-store locations such as Denver Health Pharmacy, USave ... The acquisition helps Digital Pharmacist accelerate its product ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... ... firm serving the families and businesses of the Norwalk and Vermillion areas, ... Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse prevention and ...
(Date:3/23/2017)... Yardley, PA (PRWEB) , ... March 23, 2017 ... ... received Patient Oriented Disease Management Accreditation from the NCQA. The accreditation covers StayWell’s ... programs. , Accredited status is granted to organizations that have excellent programs ...
(Date:3/23/2017)... ... , ... The TouchPoint Solution, home of Buzzies *, is boosting the ... , “Buzzies change the way we interact with stress and live our day-to-day lives,” ... date in December 2016, The TouchPoint Solution has sold more than $750,000 in product ...
(Date:3/23/2017)... ... March 23, 2017 , ... After raising more than $1.135 million ... most-funded travel pillow in crowdfunding history, has established a U.S. Headquarters in ... travel innovation to Americans. , “We’re excited to be operating on U.S. shores, where ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... for seniors, today announced rapid completion of the strategic executive team expansion needed ... notable additions to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief ...
Breaking Medicine News(10 mins):